文献速递头颈外科

新辅助化疗可改善N3期鼻咽癌患者生存

Neoadjuvant chemotherapy improves survival compared with concurrent chemoradiation alone in nasopharyngeal carcinoma patients with N3 disease.
PubMed 文献 · Head Neck · 2019-09-14

该研究基于美国国家癌症数据库5424例根治性治疗的鼻咽癌患者,评估新辅助化疗(NAC)联合放化疗(CRT)对比单纯CRT的总生存(OS)。

核心结论

  • 在非流行区鼻咽癌患者中,NAC可能改善远处微转移风险较高者的OS,尤其是N3期和不利组织学类型。

研究设计与样本

  • 回顾性队列研究,纳入美国国家癌症数据库5424例根治性治疗的鼻咽癌患者。
  • 采用多因素Cox比例风险分析预测NAC使用及对OS的影响。
  • 进行倾向评分匹配(1:2)生存分析,NAC组968例,单纯CRT组1914例。

临床怎么用

  • 对于非流行区N3期鼻咽癌患者,可考虑在CRT基础上加用NAC以改善OS。
  • 角化型组织学患者可能从NAC中获益,治疗决策时可参考组织学类型。

局限性

  • 研究为回顾性数据库分析,可能存在选择偏倚和未测量混杂因素。
  • NAC试验证据在非流行区缺乏,本研究为该人群提供了补充数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Neoadjuvant chemotherapy (NAC) trials in endemic regions of nasopharyngeal carcinoma (NPC) found improved survival, but studies are lacking in nonendemic regions. We assessed whether adding NAC to concurrent chemoradiation (CRT) improves overall survival (OS), especially in high-risk nonendemic patients. METHODS: Definitively treated NPC patients (n = 5424) from the National Cancer Database were analyzed for predictors of NAC and NAC effects on OS with multivariate Cox proportional hazards analysis (multivariate analysis [MVA]). Propensity score matched (1:2) survival analysis of NAC (n = 968) and CRT alone (n = 1914) was also performed. Effects on OS were stratified by risk group. RESULTS: On MVA, NAC-improved OS among the total cohort (hazard ratio [HR] 0.89, P = .049), particularly among stratified keratinizing histology (HR 0.82, P = .015) and N3 disease (HR 0.73, P = .046). Among propensity matched patients, NAC improved OS in patients with N3 disease (n = 336; HR 0.71, P = .046). CONCLUSIONS: NAC may improve OS among nonendemic NPC patients at higher risk of distant micrometastases, particularly N3 disease and those with unfavorable histology.

来源:Head Neck,查看原文。版权归原作者所有。

引用

  1. Han JE, Yi SK, Wang S, et al. Neoadjuvant chemotherapy improves survival compared with concurrent chemoradiation alone in nasopharyngeal carcinoma patients with N3 disease. Head Neck. 2019. PMID: 31520512. doi:10.1002/hed.25955

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。